Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia

Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustain...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Olshansky, Brian [verfasserIn] Kail, John [verfasserIn] Kopp, Douglas [verfasserIn] Wilber, David [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	1993

Schlagwörter:	Ventricular Tachycardia Antiarrhythmic Drug Flecainide Encainide Sustained Ventricular Tachycardia

Übergeordnetes Werk:	Enthalten in: Clinical drug investigation - Berlin [u.a.] : Springer, 1989, 6(1993), 3 vom: Sept., Seite 119-126
Übergeordnetes Werk:	volume:6 ; year:1993 ; number:3 ; month:09 ; pages:119-126

Links:	Volltext

DOI / URN:	10.1007/BF03259731

Katalog-ID:	SPR032998953

Internformat


LEADER	01000caa a22002652 4500
001	SPR032998953
003	DE-627
005	20230519200755.0
007	cr uuu---uuuuu
008	201007s1993 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/BF03259731 \|2 doi
035			\|a (DE-627)SPR032998953
035			\|a (SPR)BF03259731-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
084			\|a 44.40 \|2 bkl
100	1		\|a Olshansky, Brian \|e verfasserin \|4 aut
245	1	0	\|a Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia
264		1	\|c 1993
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.
650		4	\|a Ventricular Tachycardia \|7 (dpeaa)DE-He213
650		4	\|a Antiarrhythmic Drug \|7 (dpeaa)DE-He213
650		4	\|a Flecainide \|7 (dpeaa)DE-He213
650		4	\|a Encainide \|7 (dpeaa)DE-He213
650		4	\|a Sustained Ventricular Tachycardia \|7 (dpeaa)DE-He213
700	1		\|a Kail, John \|e verfasserin \|4 aut
700	1		\|a Kopp, Douglas \|e verfasserin \|4 aut
700	1		\|a Wilber, David \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Clinical drug investigation \|d Berlin [u.a.] : Springer, 1989 \|g 6(1993), 3 vom: Sept., Seite 119-126 \|w (DE-627)327645083 \|w (DE-600)2043793-6 \|x 1179-1918 \|7 nnns
773	1	8	\|g volume:6 \|g year:1993 \|g number:3 \|g month:09 \|g pages:119-126
856	4	0	\|u https://dx.doi.org/10.1007/BF03259731 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a SSG-OPC-PHA
912			\|a SSG-OPC-ASE
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2190
936	b	k	\|a 44.40 \|q ASE
951			\|a AR
952			\|d 6 \|j 1993 \|e 3 \|c 09 \|h 119-126

Indexfelder

author_variant	b o bo j k jk d k dk d w dw
matchkey_str	article:11791918:1993----::fiaynavrefetomrcznfret
hierarchy_sort_str	1993
bklnumber	44.40
publishDate	1993
allfields	10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126
spelling	10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126
allfields_unstemmed	10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126
allfieldsGer	10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126
allfieldsSound	10.1007/BF03259731 doi (DE-627)SPR032998953 (SPR)BF03259731-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Olshansky, Brian verfasserin aut Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia 1993 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects. Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213 Kail, John verfasserin aut Kopp, Douglas verfasserin aut Wilber, David verfasserin aut Enthalten in Clinical drug investigation Berlin [u.a.] : Springer, 1989 6(1993), 3 vom: Sept., Seite 119-126 (DE-627)327645083 (DE-600)2043793-6 1179-1918 nnns volume:6 year:1993 number:3 month:09 pages:119-126 https://dx.doi.org/10.1007/BF03259731 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1993 3 09 119-126
language	English
source	Enthalten in Clinical drug investigation 6(1993), 3 vom: Sept., Seite 119-126 volume:6 year:1993 number:3 month:09 pages:119-126
sourceStr	Enthalten in Clinical drug investigation 6(1993), 3 vom: Sept., Seite 119-126 volume:6 year:1993 number:3 month:09 pages:119-126
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Ventricular Tachycardia Antiarrhythmic Drug Flecainide Encainide Sustained Ventricular Tachycardia
dewey-raw	610
isfreeaccess_bool	false
container_title	Clinical drug investigation
authorswithroles_txt_mv	Olshansky, Brian @@aut@@ Kail, John @@aut@@ Kopp, Douglas @@aut@@ Wilber, David @@aut@@
publishDateDaySort_date	1993-09-01T00:00:00Z
hierarchy_top_id	327645083
dewey-sort	3610
id	SPR032998953
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032998953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200755.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1993 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259731</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032998953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259731-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Olshansky, Brian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiarrhythmic Drug</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Flecainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Encainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sustained Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kail, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopp, Douglas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilber, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">6(1993), 3 vom: Sept., Seite 119-126</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:119-126</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259731</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1993</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">119-126</subfield></datafield></record></collection>
author	Olshansky, Brian
spellingShingle	Olshansky, Brian ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia
authorStr	Olshansky, Brian
ppnlink_with_tag_str_mv	@@773@@(DE-627)327645083
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1179-1918
topic_title	610 ASE 44.40 bkl Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia Ventricular Tachycardia (dpeaa)DE-He213 Antiarrhythmic Drug (dpeaa)DE-He213 Flecainide (dpeaa)DE-He213 Encainide (dpeaa)DE-He213 Sustained Ventricular Tachycardia (dpeaa)DE-He213
topic	ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia
topic_unstemmed	ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia
topic_browse	ddc 610 bkl 44.40 misc Ventricular Tachycardia misc Antiarrhythmic Drug misc Flecainide misc Encainide misc Sustained Ventricular Tachycardia
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Clinical drug investigation
hierarchy_parent_id	327645083
dewey-tens	610 - Medicine & health
hierarchy_top_title	Clinical drug investigation
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)327645083 (DE-600)2043793-6
title	Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia
ctrlnum	(DE-627)SPR032998953 (SPR)BF03259731-e
title_full	Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia
author_sort	Olshansky, Brian
journal	Clinical drug investigation
journalStr	Clinical drug investigation
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	1993
contenttype_str_mv	txt
container_start_page	119
author_browse	Olshansky, Brian Kail, John Kopp, Douglas Wilber, David
container_volume	6
class	610 ASE 44.40 bkl
format_se	Elektronische Aufsätze
author-letter	Olshansky, Brian
doi_str_mv	10.1007/BF03259731
dewey-full	610
author2-role	verfasserin
title_sort	efficacy and adverse effects of moracizine for ventricular tachycardia
title_auth	Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia
abstract	Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.
abstractGer	Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.
abstract_unstemmed	Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190
container_issue	3
title_short	Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia
url	https://dx.doi.org/10.1007/BF03259731
remote_bool	true
author2	Kail, John Kopp, Douglas Wilber, David
author2Str	Kail, John Kopp, Douglas Wilber, David
ppnlink	327645083
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/BF03259731
up_date	2024-07-03T15:57:29.028Z
_version_	1803574049804124160
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR032998953</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200755.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1993 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/BF03259731</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR032998953</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)BF03259731-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Olshansky, Brian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Moracizine (mean dose 792 ± 84mg, range 600 to 900 mg/day) was evaluated in 18 patients aged 62 ± 7 years for spontaneous nonsustained (n = 3) or sustained monomorphic (n = 12) ventricular tachycardia, cardiac arrest (n = 1) or syncope (n = 2). All patients had spontaneous or induced sustained monomorphic ventricular tachycardia. Diagnoses included coronary artery disease (n = 7) and dilated cardiomyopathy (n = 4), valvular heart disease (n = 2), myocarditis (n = 1), or a combination of these (n = 4). The mean left ventricular ejection fraction was 32 ± 9% (range 15 to 52%). Prior to moracizine, antiarrhythmic drug administration included a mean of 2 ± 1 trials with class IA (n = 17), IB or IA + IB (n = 6) or IC (n = 5) antiarrhythmic drugs, or amiodarone (n = 3). Prior antiarrhythmic drugs were discontinued for either the occurrence of noncardiac side effects or lack of efficacy. On moracizine, new sustained monomorphic ventricular tachycardia occurred in 3 patients with previous nonsustained ventricular tachycardia; spontaneous sustained monomorphic ventricular tachycardia recurred in 5 (and appeared to be worse in at least 2) patients with previous sustained monomorphic ventricular tachycardia; sustained monomorphic ventricular tachycardia was induced in all 11 patients undergoing repeat electrophysiology testing and was more difficult to terminate in 2 patients; 1 patient with an implantable defibrillator died suddenly after receiving multiple implantable defibrillator shocks while on moracizine despite recent electrophysiology testing demonstrating satisfactory defibrillation thresholds. Serious arrhythmic events occurred in 7 patients within 7 days of therapy with the drug. In this patient population with inducible or spontaneous sustained monomorphic ventricular tachycardia, moracizine was not effective and caused frequent, serious (usually early) pro-arrhythmic effects.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiarrhythmic Drug</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Flecainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Encainide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sustained Ventricular Tachycardia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kail, John</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopp, Douglas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wilber, David</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Clinical drug investigation</subfield><subfield code="d">Berlin [u.a.] : Springer, 1989</subfield><subfield code="g">6(1993), 3 vom: Sept., Seite 119-126</subfield><subfield code="w">(DE-627)327645083</subfield><subfield code="w">(DE-600)2043793-6</subfield><subfield code="x">1179-1918</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:3</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:119-126</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/BF03259731</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1993</subfield><subfield code="e">3</subfield><subfield code="c">09</subfield><subfield code="h">119-126</subfield></datafield></record></collection>
score	7.399766

Nicht das Richtige dabei?

Schreiben Sie uns!

Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?